TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16646120
Drug: Intensive mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive mental activity (daily memorization of prose passages and demanding mental arithmetic) for 2 weeks
Study: 2003591
Drug: Naloxone (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (1.2 mg iv bolus)
Study: 7025090
Drug: Methylglucamine metrizoate
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylglucamine metrizoate (Isopaque Cerebral, 280 mg I/mI)
Study: 7025090
Drug: Metrizamide (Amipaque,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrizamide (Amipaque, 280 mg I/mI)
Study: 29187584
Drug: BsAb-5 (bispecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: BsAb-5 (bispecific antibody targeting c-MET and CTLA-4)
Study: 27563831
Drug: Tailored exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored exercise therapy (20-week individualized, comorbidity-adapted exercise program consisting of aerobic and strength training and training of daily activities)
Study: 24209639
Drug: Fasting for
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting for 2 hours (F2) with 200 ml of clear liquids ingested 2 hours before the procedure
Study: 9848065
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid therapy (short-time)
Study: 9848065
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid therapy (long-time)
Study: 9848065
Drug: Systemic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroid therapy (bolus group)
Study: 9848065
Drug: Systemic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroid therapy (tapering group)
Study: 2576886
Drug: Somatostatin (SMS)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SMS) administered epidurally
Study: 2576886
Drug: Somatostatin (SMS)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SMS) administered epidurally in group A (procto-anal)
Study: 2576886
Drug: Somatostatin (SMS)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SMS) administered epidurally in group B (inguino-crural)
Study: 31120614
Drug: Continuous ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ropivacaine (0.2% at 4‐6 ml/h)
Study: 28012403
Drug: Basal-bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus therapy based on analog insulin (detemir/aspart)
Study: 28012403
Drug: Basal-bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus therapy based on human insulin (NPH/regular)
Study: 28012403
Drug: Analog insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analog insulin treatment
Study: 28012403
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin treatment
Study: 28012403
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (analog and human insulin)
Study: 26046455
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% with fentanyl 5 μg/mL
Study: 26046455
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% with fentanyl 5 μg/mL and epinephrine 5 μg/mL
Study: 21789429
Drug: 0.8 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg/day of soy protein
Study: 21789429
Drug: 0.8 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg/day of soy protein plus fibers
Study: 21789429
Drug: 0.8 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg/day of animal protein
Study: 11437696
Drug: Newer 5-ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer 5-ASA formulations
Study: 11437696
Drug: 5-ASA-containing preparations
Normalized name: Caviar Preparation
DrugBank: Caviar, unspecified (DB14241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA-containing preparations
Study: 9678070
Drug: 0.28 mg
Normalized name: amitraz 0.28 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.28 mg ethinylestradiol monthly + 12.5 mg/day cyproterone acetate for the first 10 days of treatment each month
Study: 9678070
Drug: 0.32 mg
Normalized name: gonadorelin 0.32 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.32 mg ethinylestradiol monthly + 12.5 mg/day cyproterone acetate for the first 10 days of treatment each month
Study: 9678070
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (0.28 mg and 0.32 mg ethinylestradiol)
Study: 8026301
Drug: Ethanol 1.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 1.00 g/kg
Study: 2530317
Drug: Intravenous floxuridine
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous floxuridine (IV FUDR)
Study: 29049935
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (IN-OT) 36 IU daily for 4-6 weeks
Study: 23563576
Drug: LCZ696 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 200 mg b.i.d.
Study: 23563576
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg b.i.d.
Study: 22825654
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) administered orally prior to FDG-PET in 65 patients
Study: 19936917
Drug: UFT (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (oral tegafur-uracil) for 2 years
Study: 15956984
Drug: Amoxapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxapine (up to 250 mg/day)
Study: 15956984
Drug: Risperidone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (up to 5 mg/day)
Study: 12385688
Drug: pivmecillinam 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivmecillinam 200 mg tid for 7 days
Study: 12385688
Drug: pivmecillinam 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivmecillinam 200 mg bid for 7 days
Study: 12385688
Drug: pivmecillinam 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: pivmecillinam 400 mg bid for 3 days
Study: 12385688
Drug: norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: norfloxacin 400 mg bid for 3 days
Study: 10447316
Drug: Interferon-alpha treatment
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha treatment for at least 24 weeks
Study: 10447316
Drug: Negative qualitative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative qualitative HCV RNA test after 12 weeks of interferon treatment
Study: 10447316
Drug: Prolonged treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged treatment with interferon-alpha (> 6 months)
Study: 7839429
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose arginine vasopressin (AVP) infusion, n = 11
Study: 7839429
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose arginine vasopressin (AVP) infusion
Study: 2201722
Drug: Zopiclone 7.5
Normalized name: zopiclone 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 7.5 mg with ethanol (0.2‐0.4 g/kg)
Study: 2201722
Drug: Nitrazepam 5
Normalized name: nitrazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam 5 mg with ethanol (0.2‐0.4 g/kg)
Study: 2201722
Drug: Ethanol alone
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol alone (0.2‐0.4 g/kg)
Study: 2201722
Drug: Zopiclone 7.5
Normalized name: zopiclone 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 7.5 mg and Nitrazepam 5 mg with ethanol
Study: 28283596
Drug: IncobotulinumtoxinA (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA (all doses)
Study: 28823623
Drug: J-Tip Needleless
Normalized name: hydroxypropyl cellulose (type J)
Approvals — FDA: no, EMA: no, PMDA: no
Description: J-Tip Needleless Injection System®
Study: 25929699
Drug: Appropriate shock
Normalized name: house dust allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate shock therapy in women
Study: 25929699
Drug: Appropriate shock
Normalized name: house dust allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate shock therapy in men
Study: 23761424
Drug: Antagonist coactivation
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antagonist coactivation percentage
Study: 22029549
Drug: Atomoxetine 25-100
Normalized name: atomoxetine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 25-100 mg (mean final dose = 89.9 mg)
Study: 22029549
Drug: On-treatment drinking
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment drinking levels
Study: 18284391
Drug: Sodium carboxymethylcellulose
Normalized name: Carboxymethylcellulose Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium carboxymethylcellulose hydrocolloid polymer treatment
Study: 11115954
Drug: RTV 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTV 200 mg once daily (group A)
Study: 11115954
Drug: RTV 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTV 400 mg once daily (group B)
Study: 11115954
Drug: Indinavir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 800 mg (day 1), 400 mg (day 15), 800 mg (day 18), 1200 mg (day 21)
Study: 11115954
Drug: Indinavir 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 1200 mg/400 mg RTV
Study: 11115954
Drug: Indinavir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 800 mg/400 mg RTV or 1200 mg/200 mg RTV
Study: 2420106
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (TRH) continuous infusion (400 micrograms bolus followed by 200 micrograms/hour for 6 hours)
Study: 20889343
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of certainty and high supra-postural task constraint
Study: 8785030
Drug: Local intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Local intra-arterial injection of cisplatin at a dose of 100 mg concomitant with hemodialysis (HD)
Study: 8785030
Drug: Local intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Local intra-arterial injection of cisplatin at doses of 200 or 250 mg concomitant with hemodialysis (HD)
Study: 8785030
Drug: Local intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Local intra-arterial injection of cisplatin (dose not specified) without concomitant hemodialysis (HD)
Study: 20924975
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (200 mg daily for 6 months)
Study: 11755589
Drug: Load cycling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Load cycling (90N for 5000 cycles) with Prompt L-Pop
Study: 11755589
Drug: Non-load cycling
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-load cycling (control group) with Prompt L-Pop
Study: 3015041
Drug: COM-ANV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: COM-ANV therapy
Study: 3015041
Drug: ANV-COM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANV-COM therapy
Study: 3015041
Drug: ANV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANV therapy
Study: 27347788
Drug: TRANSITECH (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRANSITECH (2 tablets daily for 10 days)
Study: 18922425
Drug: Levosimendan infusion
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan infusion (0.2 microg/kg/min) for 24 hours
Study: 15618526
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment group
Study: 9590840
Drug: 1% miconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% miconazole suspension
Study: 1747568
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND; 50 mg IM every three weeks)
Study: 1747568
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group 1 (CST therapy for less years)
Study: 28089425
Drug: Laryngeal Mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laryngeal Mask Airway I‐Gel
Study: 24063835
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol); n = 700
Study: 24063835
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (aspirin and clopidogrel); n = 699
Study: 19691668
Drug: Viusid (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viusid (three sachets daily) with hypocaloric diet and aerobic exercise
Study: 28138980
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of canagliflozin
Study: 28138980
Drug: Twice-daily dosing
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosing of canagliflozin
Study: 28138980
Drug: Canagliflozin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (both dosing regimens)
Study: 21736448
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) administration of erythropoietin (EPO) for 4 months
Study: 21736448
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) administration of erythropoietin (EPO) for 4 months
Study: 18443671
Drug: CR tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR tramadol (150 mg daily, titrated to a maximum of 400 mg once daily)
Study: 10638884
Drug: Maximal bilevel
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal bilevel training (45 minutes daily, 5 days a week for 6 weeks, working 2.03+/‐0.4 kJ/kg per session)
Study: 10638884
Drug: O2 cart
Approvals — FDA: no, EMA: no, PMDA: no
Description: O2 cart pushers (45 minutes daily, 5 days a week for 6 weeks, working 1.44+/‐.35 kJ/kg per session)
Study: 9338536
Drug: Prophylactic inhaled
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic inhaled steroids
Study: 1524961
Drug: Plain prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain prednisolone tablets (30 mg)
Study: 1524961
Drug: Enteric-coated prednisolone
Normalized name: prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated prednisolone tablets (30 mg)
Study: 1524961
Drug: Plain and
Normalized name: VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain and enteric-coated prednisolone tablets (30 mg)
Study: 3156329
Drug: Bolus intravenous
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intravenous injection of fibronectin (1 mg/kg)
Study: 3156329
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of one-half of the dose followed by continuous infusion of the remaining half-dose over a 6-hour period (group B + P)
Study: 27159166
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) immunization with CN54 gp140 at 20 or 100 μg co-administered with Glucopyranosyl Lipid Adjuvant (GLA)
Study: 27159166
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) immunization with CN54 gp140 and 0.5% chitosan
Study: 27159166
Drug: Intravaginal (IVAG)
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal (IVAG) immunization with CN54 gp140 in an aqueous gel
Study: 27159166
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) boosting after IN priming
Study: 24107072
Drug: GSK2336805 (monotherapy)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2336805 (monotherapy)
Study: 22784346
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Mahatma Gandhi Mission Hospital treatment)
Study: 20833796
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of alcohol (target BAC = .10%)
Study: 16164447
Drug: salbutamol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol (5 mg/mL)
Study: 12753877
Drug: Tramadol/acetaminophen combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/acetaminophen combination tablets (37.5 mg tramadol/325 mg acetaminophen)
Study: 23441841
Drug: Berberine 500
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine 500 mg twice a day for 3 months
Study: 19375278
Drug: Exercise-only control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise-only control treatment
Study: 11495220
Drug: Low-fat, high-fiber,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, high-fiber, high-fruit/vegetable diet (20% of energy from fat, 18 g/1,000 kcal/day fiber, 3.5 servings/1,000 kcal/day fruit/vegetable)
Study: 7812890
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 2% eye drops, administered twice daily for 4 weeks
Study: 3235806
Drug: Sterile technique
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile technique for preparation of the skin over the vascular access site
Study: 3235806
Drug: Clean technique
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clean technique for preparation of the skin over the vascular access site
Study: 8400973
Drug: Metoprolol 50‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50‐100 mg twice daily
Study: 8400973
Drug: Isradipine 2.5‐5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 2.5‐5.0 mg twice daily
Study: 8400973
Drug: Calcium entry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium entry blockers
Study: 29094444
Drug: Metformin (MTF)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MTF) 1700 mg/day
Study: 26847305
Drug: Ultrasound-guided steroid
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided steroid injection into scalene muscles
Study: 22508732
Drug: Epidural steroids
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroids
Study: 16848109
Drug: Pasteurized cow
Normalized name: Pasteurized cow's milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasteurized cow milk yogurt (15 ml/kg/day) plus routine hospital treatment
Study: 16848109
Drug: Routine hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine hospital treatment
Study: 14685931
Drug: No treatment/conversation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment/conversation only
Study: 10973843
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (nitrendipine, with possible addition of enalapril, hydrochlorothiazide, or both)
Study: 8451663
Drug: Two-component acellular
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-component acellular pertussis vaccine (LPF/FHA)
Study: 8451663
Drug: Standard whole-cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard whole-cell pertussis vaccine
Study: 2434108
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered human pepsinated immunoglobulin G (HPIG, Gamma‐Venin)
Study: 2434108
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified what treatment or intervention was used)
Study: 30259623
Drug: Exenatide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 2.5 mcg
Study: 23462720
Drug: Intraperitoneal (IP)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (IP) chemotherapy with cisplatin and paclitaxel
Study: 23462720
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) chemotherapy with paclitaxel and cisplatin
Study: 21289328
Drug: Tolvaptan (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (in patients with serum sodium concentration of <130 meq/L)
Study: 21289328
Drug: More severely
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More severely hyponatremic patients (serum sodium concentration of <135 meq/L) receiving placebo
Study: 19260800
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg administered 1 hour before SWL and 24 hours later
Study: 19260800
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pretreatment medications)
Study: 11502641
Drug: O(2) administration
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O(2) administration
Study: 8303624
Drug: MK-0679 (825
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0679 (825 mg, orally)